Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EvolusEOLS +0.54%73 EV-to-OCF is -43.85 as of Aug. 23, 2026. GuruFocus rates EOLS with a GF Score™ of 73/100 and a GF Value™ of $13.34 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Evolus ranks better than 93.03% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Evolus's Enterprise Value is $674.5 Mil.
Evolus's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-15.4 Mil. Therefore, Evolus's EV-to-OCF for today is -43.85.
The historical rank and industry rank for Evolus's EV-to-OCF or its related term are showing as below:
EOLS'
s EV-to-OCF Range Over the Past 10 Years
Min: -66.61 Med: -10.22 Max: -0.84
Current: -43.85
During the past 11 years, the highest EV-to-OCF of Evolus was -0.84. The lowest was -66.61. And the median was -10.22.
EOLS's EV-to-OCF is ranked better than 93.03% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 10.68
vs EOLS: -43.85
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-23), Evolus's stock price is $8.40.
Evolus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.520. Therefore, Evolus's PE Ratio (TTM) for today is At Loss.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Evolus's share price for today is $8.40.
Evolus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.520.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Evolus EV-to-OCF Related Terms
Evolus EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Evolus's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Evolus's EV-to-OCF falls into.
Evolus's current Enterprise Value is $674.5 Mil.
Evolus's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolus (EOLS) has a EV-to-OCF of -43.85 as of Aug. 23, 2026. According to the industry distribution chart, Evolus ranks #70 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 7%.
Is Evolus' EV-to-OCF too high?
Evolus' current EV-to-OCF is -43.85. Based on the distribution chart, Evolus ranks #70 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Evolus has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' EV-to-OCF compare to EBS and ELTP?
According to the Drug Manufacturers industry distribution chart, Evolus ranks #70 out of 1005 companies for EV-to-OCF. This places Evolus in the top 7% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 10.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.68, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolus's current EV-to-OCF is -43.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.34, compared to a current price of $8.40 — trading 37% below its estimated fair value. The current EV-to-OCF is -43.85. Evolus' overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Evolus (EOLS), the current EV-to-OCF is -43.85 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolus (EOLS) Overvalued in 2026?
Based on GuruFocus' analysis, Evolus stock appears to be undervalued.
The current stock price of $8.40 is trading 37% below its estimated GF Value™ of $13.34.
GuruFocus considers Evolus to be Possible Value Trap.
Key valuation signals for EOLS:
EV-to-OCF: -43.85
GF Value™: $13.34 vs. price of $8.40 (37% below fair value)
No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
73GF Score
Get the complete analysis for EOLS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EOLS has been successfully added to your 
